The following mouse antibodies were used: anti-CD25 (PC61, 102006), anti-IFNγ (XMG1.2, 505806), anti-CD103 (2E7, 121420), anti-GITR (YGITR765, 120205), anti-CD44 (IM7, 103008), anti-IL-4 (11B11, 504104), anti-CD4 (GK1.5, 100434), anti-CD25 (PC61, 102029), anti-IL-5 (TRFK5, 504303), anti-CD62L (MEL-14, 104412), anti-CD69 (H1.2F3, 104513), anti-Gr1 (RB6-8C5, 108411), anti-CD103 (2E7, 121403), anti-IL-17A (TC11-18H10.1, 506916), anti-GITR (DTA-1, 126311), anti-CD304 (Nrp1) (3E12, 145209), anti-CD3ε (145-2C11, 100334), anti-CD19 (6D5, 115519), anti-CD152 (CTLA4) (UC10-4B9, 106313), anti-B220 (RA3-6B2, 103224), streptavidin-PerCP (405213), anti-KLRG1 (2F1/KLRG1, 138409), anti-CD11b (M1/70, 101215), anti-Helios (22F6, 137216), anti-CD154 (CD40L) (MR1, 106505), anti-CD120a (TNFRI) (55R-286, 113003), anti-CD120b (TNFRII) (TR75-89, 113405), anti-CD262 (DR5, TRAIL-R2) (MD5-1, 119905), and anti-CD3ε (145-2C11, 100333) (all from BioLegend); anti-CD3ε (145-2C11, 553062), anti-CD11b (M1/70, 553310), anti-B220 (RA3-6B2, 11-0452-82), anti-CD5 (53-7.3, 553022), anti-CD25 (PC61, 552880), anti-CD8α (53-6.7, 552877), anti-CD19 (1D3, 562701), streptavidin-APC-Cy7 (554063), anti-CD69 (H1.2F3, 553237), anti-CD95 (Fas) (Jo2, 554258), and anti-SiglecF (E50-2440, 552126) (all from BD Biosciences); anti-TCRβ (H57-597, 11-5961-82), anti-CD25 (PC61.5, 12-0251-82), anti-Ki-67 (SolA15, 12-5698-80), anti-IFNγ (XMG1.2, 12-7311-81), anti-CD4 (RM4-5, 17-0042-82), anti-B220 (RA3-6B2, 17-0452-83), anti-IL-13 (eBio13A, 50-7133-80), anti-γδTCR (eBioGL3, 13-5711-81), streptavidin-APC (17-4317-82), anti-NK1.1 (PK136, 17-5941-81), anti-CD45RB (C363.16A, 12-0455-82), anti-Foxp3 (FJK-16s, 11-5773-82), anti-CD19 (eBio1D3, 11-0193-82), anti-TCRβ (H57-597, 12-5961-82), anti-IL-2 (JES6-5H4, 12-7021-81), streptavidin-PE (12-4317-87), anti-CD62L (MEL-14, 13-0621-82), anti-NK1.1 (PK136, 13-5941-82), anti-TNFα (MP6-XT22, 17-7321-81), anti-IL-10 (JES5-16E3, 17-7101-81), and anti-IFNγ (XMG1.2, 17-7311-81) (all from eBioscience); anti-CD127 (A7R34, 50-1271-U025) (TONBO Biosciences); and anti-p-ERK (D13.14.4E, 4344), anti-p-p65 (93H1, 4886), and anti-IκBα (L35A5, 7523) (all from Cell Signaling Technology). All antibodies used for flow cytometory analysis were diluted at 1:200 before staining.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.